Profile data is unavailable for this security.
About the company
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
- Revenue in USD (TTM)658.62m
- Net income in USD-156.38m
- Incorporated1994
- Employees3.30k
- LocationAzenta Inc200 Summit Drive, 6Th FloorBURLINGTON 01803United StatesUSA
- Phone+1 (978) 262-2400
- Fax+1 (302) 636-5454
- Websitehttps://www.azenta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novavax Inc | 987.67m | -294.33m | 2.18bn | 1.54k | -- | -- | -- | 2.21 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Vera Therapeutics Inc | 0.00 | -107.85m | 2.24bn | 72.00 | -- | 6.83 | -- | -- | -2.20 | -2.20 | 0.00 | 5.98 | 0.00 | -- | -- | 0.00 | -36.41 | -- | -39.42 | -- | -- | -- | -- | -- | -- | -- | 0.1329 | -- | -- | -- | -7.79 | -- | -- | -- |
| Keros Therapeutics Inc | 271.00k | -168.05m | 2.29bn | 149.00 | -- | 5.23 | -- | 8,432.09 | -5.13 | -5.13 | 0.0082 | 11.64 | 0.0007 | -- | -- | 1,992.65 | -41.43 | -35.95 | -43.43 | -38.07 | -- | -- | -62,012.55 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.34bn | 525.00 | -- | 7.07 | -- | 119.08 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Janux Therapeutics Inc | 15.13m | -44.05m | 2.35bn | 64.00 | -- | 3.57 | -- | 155.25 | -0.9152 | -0.9152 | 0.3088 | 12.61 | 0.0293 | -- | -- | 236,359.40 | -8.53 | -- | -8.78 | -- | -- | -- | -291.17 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 31.31m | -364.93m | 2.35bn | 383.00 | -- | 3.56 | -- | 75.10 | -6.49 | -6.49 | 0.5568 | 11.61 | 0.0337 | 0.1687 | 10.41 | 81,738.91 | -39.28 | -29.54 | -41.94 | -31.88 | 89.33 | -- | -1,165.69 | -3,826.10 | 9.71 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Azenta Inc | 658.62m | -156.38m | 2.36bn | 3.30k | -- | 1.22 | -- | 3.59 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Neumora Therapeutics Inc | 0.00 | -274.18m | 2.36bn | 108.00 | -- | 6.19 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Immunitybio Inc | 1.31m | -597.65m | 2.39bn | 622.00 | -- | -- | -- | 1,826.54 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| SpringWorks Therapeutics Inc | 86.19m | -301.06m | 2.42bn | 305.00 | -- | 4.35 | -- | 28.13 | -4.44 | -4.44 | 1.25 | 7.50 | 0.1519 | -- | -- | 282,577.10 | -53.07 | -36.97 | -57.99 | -39.49 | 95.27 | -- | -349.32 | -2,176.46 | 7.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| CG Oncology Inc | 650.00k | -75.84m | 2.46bn | 61.00 | -- | 4.42 | -- | 3,780.05 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.46bn | 136.00 | -- | 2.67 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 890.53m | 30.57m | 2.50bn | 630.00 | 83.28 | 4.85 | 59.60 | 2.81 | 0.1813 | 0.1813 | 5.38 | 3.12 | 1.14 | 1.83 | 9.60 | 1,491,682.00 | 3.93 | -27.50 | 5.93 | -32.73 | 91.72 | 95.62 | 3.43 | -38.35 | 1.95 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Veracyte Inc | 399.58m | -54.04m | 2.52bn | 815.00 | -- | 2.23 | -- | 6.31 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Ideaya Biosciences Inc | 11.96m | -153.74m | 2.53bn | 124.00 | -- | 2.45 | -- | 211.70 | -2.18 | -2.18 | 0.1718 | 12.24 | 0.0159 | -- | 148.57 | 96,451.61 | -20.48 | -19.17 | -21.42 | -21.05 | -- | -- | -1,285.44 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Data as of Oct 07 2024. Currency figures normalised to Azenta Inc's reporting currency: US Dollar USD
56.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.27m | 9.78% |
| Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 2024 | 5.20m | 9.64% |
| Politan Capital Management LPas of 31 Mar 2024 | 4.61m | 8.55% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.47m | 8.30% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 2.83m | 5.26% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.16m | 4.01% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.74m | 3.22% |
| GW&K Investment Management LLCas of 31 Mar 2024 | 1.52m | 2.82% |
| Conestoga Capital Advisors LLCas of 30 Jun 2024 | 1.28m | 2.38% |
| Allspring Global Investments LLCas of 30 Jun 2024 | 1.12m | 2.07% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
